<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006172</url>
  </required_header>
  <id_info>
    <org_study_id>GO39374</org_study_id>
    <secondary_id>2016-003022-17</secondary_id>
    <nct_id>NCT03006172</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase I study designed to evaluate the safety,&#xD;
      tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in&#xD;
      patients with locally advanced or metastatic PIK3CA-mutant solid tumors, including breast&#xD;
      cancer, and in combination with standard-of-care endocrine and/or targeted therapies for the&#xD;
      treatment of locally advanced or metastatic PIK3CA-mutant breast cancer. Participants will be&#xD;
      enrolled in two stages: a dose-escalation stage (Stage I) and an expansion stage (Stage II).&#xD;
      Participants will be assigned to one of seven regimens: inavolisib as a single agent (Arm A),&#xD;
      inavolisib in combination with palbociclib and letrozole (Arm B), inavolisib in combination&#xD;
      with letrozole (Arm C), inavolisib in combination with fulvestrant (Arm D), inavolisib in&#xD;
      combination with palbociclib and fulvestrant (Arm E), inavolisib in combination with&#xD;
      palbociclib, fulvestrant, and metformin (Arm F), and inavolisib in combination with&#xD;
      trastuzumab and pertuzumab (and letrozole or fulvestrant, if applicable (Arm G)).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Percentage of Participants With Dose Limiting Toxicities</measure>
    <time_frame>Day 1 up to Day 28 (for Stage 1 Arm A: Day 1 up to Day 35)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose of Inavolisib</measure>
    <time_frame>Day 1 up to Day 28 (for Stage 1 Arm A: Day 1 up to Day 35)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>Day 1 up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time-Curve (AUC) from Time Zero to Infinity (AUCinf) of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to end of study (EOS; up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from Time Zero to Dosing Interval (AUC0-tau) of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin) of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (tmax) of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of Inavolisib</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (AR) of Inavolisib at Steady-State</measure>
    <time_frame>Predose (0-2 hours before dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days (Cycle 1 of Stage 1 Arm A=35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Palbociclib</measure>
    <time_frame>Predose (0-2 hours before inavolisib) dosing) on Cycle 1 Day 1 up to Cycle 6; Cycle length=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Palbociclib</measure>
    <time_frame>Predose (0-2 hours before inavolisib) dosing) on Cycle 1 Day 1 up to Cycle 6; Cycle length=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Letrozole</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Letrozole</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Fulvestrant</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Fulvestrant</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v1.1)</measure>
    <time_frame>Baseline up to occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions &gt;/=4 weeks apart (up to approximately 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, as Assessed by RECIST v1.1</measure>
    <time_frame>From first occurrence of a documented objective response (CR or PR) to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Benefit as Assessed by RECIST v1.1</measure>
    <time_frame>Baseline up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as Assessed by RECIST v1.1</measure>
    <time_frame>Baseline up to disease progression or death from any cause, whichever occurs first (up to approximately 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Standard Uptake Value (SUV) of Tumor Regions of Interest (as assessed by [18] F-fluorodeoxyglucose-positron emission tomography) From Baseline to Approximately 2 Weeks of Inavolisib Treatment</measure>
    <time_frame>Baseline, Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Pertuzumab</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Pertuzumab</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Trastuzumab</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Trastuzumab</measure>
    <time_frame>Predose (0-2 hours before inavolisib dosing) on Cycle 1 Day 1 up to EOS (up to approximately 6 years); Cycle length=21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Stage I Arm A: Inavolisib Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I Arm C: Inavolisib + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Arm C: Inavolisib + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Arm D: Inavolisib + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inavolisib</intervention_name>
    <description>Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).</description>
    <arm_group_label>Stage I Arm A: Inavolisib Single Agent</arm_group_label>
    <arm_group_label>Stage I Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_label>Stage I Arm C: Inavolisib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm C: Inavolisib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm D: Inavolisib + Fulvestrant</arm_group_label>
    <arm_group_label>Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant</arm_group_label>
    <arm_group_label>Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin</arm_group_label>
    <arm_group_label>Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab</arm_group_label>
    <other_name>RO7113755, GDC-0077</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.</description>
    <arm_group_label>Stage II Arm D: Inavolisib + Fulvestrant</arm_group_label>
    <arm_group_label>Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant</arm_group_label>
    <arm_group_label>Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.</description>
    <arm_group_label>Stage I Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_label>Stage I Arm C: Inavolisib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm C: Inavolisib + Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.</description>
    <arm_group_label>Stage I Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm B: Inavolisib + Palbociclib + Letrozole</arm_group_label>
    <arm_group_label>Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant</arm_group_label>
    <arm_group_label>Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.</description>
    <arm_group_label>Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evaluable or measurable disease per RECIST, Version 1.1 (measurable disease only for&#xD;
             Arm D)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of greater than or equal to (â‰¥) 12 weeks&#xD;
&#xD;
          -  Adequate hematologic and organ function, including blood counts, liver and kidney&#xD;
             function&#xD;
&#xD;
        Stage I Arm A (Inavolisib):&#xD;
&#xD;
        - Locally advanced, recurrent, or metastatic, PIK3CA mutant, incurable solid tumor&#xD;
        malignancy, including breast cancer&#xD;
&#xD;
        Stages I and II, Arms B and C:&#xD;
&#xD;
        - Postmenopausal female participants with locally advanced or metastatic PIK3CA-mutant&#xD;
        HR+/HER2- breast cancer&#xD;
&#xD;
        Stage II, Arms D, E, or F:&#xD;
&#xD;
        - Female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast&#xD;
        cancer&#xD;
&#xD;
        Stage II Arm D:&#xD;
&#xD;
        - Prior treatment with CDK4/6 inhibitor&#xD;
&#xD;
        Stage II Arm G:&#xD;
&#xD;
          -  Female participants with locally advanced or metastatic PIK3CA-mutant HER2+ breast&#xD;
             cancer&#xD;
&#xD;
          -  Left ventricular ejection fraction 50% or greater&#xD;
&#xD;
        Stages I and II:&#xD;
&#xD;
        - All participants must provide tumor tissue from the primary or metastatic tumor site&#xD;
        obtained from a prior or new biopsy or surgical procedure for detection of PIK3CA mutation&#xD;
        by central laboratory test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metaplastic breast cancer&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Type 1 or 2 diabetes requiring anti-hyperglycemic medication&#xD;
&#xD;
          -  Inability or unwillingness to swallow pills&#xD;
&#xD;
          -  Malabsorption syndrome or other condition that would interfere with enteral absorption&#xD;
&#xD;
          -  Known and untreated, or active central nervous system metastases&#xD;
&#xD;
          -  Uncontrolled pleural effusion or ascites&#xD;
&#xD;
          -  Any active infection that could impact patient safety or serious infection requiring&#xD;
             intravenous antibiotics&#xD;
&#xD;
          -  History of other malignancy within 5 years, except for treated carcinoma in situ of&#xD;
             the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer&#xD;
&#xD;
          -  History of or active ventricular dysrhythmias or congestive heart failure requiring&#xD;
             medication or symptomatic coronary heart disease&#xD;
&#xD;
          -  Congenital long QT syndrome, prolonged QT interval, or family history of sudden&#xD;
             unexplained death or long QT syndrome&#xD;
&#xD;
        Stage II Arms B, C, D, and E only:&#xD;
&#xD;
          -  Prior treatment with &gt;1 chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  Prior treatment with PI3K inhibitor&#xD;
&#xD;
          -  History of significant toxicity related to mTOR inhibitor requiring treatment&#xD;
             discontinuation&#xD;
&#xD;
        Stage II Arms B and E only:&#xD;
&#xD;
        - Prior CDK4/6 inhibitor treatment&#xD;
&#xD;
        Stage II Arm G only:&#xD;
&#xD;
          -  Current uncontrolled hypertension or unstable angina&#xD;
&#xD;
          -  History of congestive heart failure, serious cardiac arrhythmia, or recent myocardial&#xD;
             infarction&#xD;
&#xD;
          -  Prior ejection fraction decrease on trastuzumab&#xD;
&#xD;
          -  Prior cumulative doxorubicin greater than 360 mg/m2&#xD;
&#xD;
          -  Symptomatic active lung disease&#xD;
&#xD;
          -  History of significant toxicity related to trastuzumab and/or pertuzumab requiring&#xD;
             discontinuation of treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO39374 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philippe Bedard Clinic Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust.</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - London</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Surrey</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIK3CA mutant, Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

